Rothschild Investment LLC Acquires 1,642 Shares of Amgen Inc. (NASDAQ:AMGN)

Rothschild Investment LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 60,259 shares of the medical research company’s stock after acquiring an additional 1,642 shares during the period. Amgen accounts for 1.0% of Rothschild Investment LLC’s portfolio, making the stock its 17th largest holding. Rothschild Investment LLC’s holdings in Amgen were worth $15,706,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. IFP Advisors Inc raised its position in shares of Amgen by 6.2% during the 4th quarter. IFP Advisors Inc now owns 6,102 shares of the medical research company’s stock valued at $1,591,000 after purchasing an additional 357 shares during the period. Mainstay Capital Management LLC ADV raised its position in shares of Amgen by 3.6% during the 4th quarter. Mainstay Capital Management LLC ADV now owns 4,980 shares of the medical research company’s stock valued at $1,298,000 after purchasing an additional 171 shares during the period. B&D White Capital Company LLC bought a new stake in shares of Amgen during the 4th quarter valued at $1,173,000. Birchcreek Wealth Management LLC raised its position in shares of Amgen by 40.3% during the 4th quarter. Birchcreek Wealth Management LLC now owns 1,261 shares of the medical research company’s stock valued at $329,000 after purchasing an additional 362 shares during the period. Finally, Y Intercept Hong Kong Ltd raised its position in shares of Amgen by 470.5% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 15,809 shares of the medical research company’s stock valued at $4,120,000 after purchasing an additional 13,038 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the sale, the executive vice president now owns 44,186 shares of the company’s stock, valued at $13,025,590.94. The trade was a 16.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock worth $20,644,335 in the last 90 days. 0.69% of the stock is owned by corporate insiders.

Amgen Price Performance

AMGN stock opened at $303.01 on Monday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The company has a 50-day moving average price of $276.27 and a 200 day moving average price of $300.31. The stock has a market cap of $162.78 billion, a PE ratio of 40.13, a P/E/G ratio of 2.58 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities research analysts anticipate that Amgen Inc. will post 20.6 earnings per share for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.14%. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on AMGN shares. Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 target price on shares of Amgen in a research note on Tuesday, November 12th. Piper Sandler raised their target price on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Finally, Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $314.09.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.